New study shows empagliflozin and dapagliflozin have comparable risk of liver-related complications, with only marginally greater improvement in fatty liver with empagliflozin, in adults with type 2 diabetes and MASLD. #MASLD #SGLT2i #T2D #LiverHealth link.springer.com/article/10.1...

Secondary analysis of the #Basel-PMI and #PMI-Vital cohorts, led by Haziri et al: increased risk of 90-day cardiac complications if #SGLT2i are stopped before anaesthesia as per current recommendations.

https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00353-3/fulltext

🧠 Could SGLT2 inhibitors offer neuroprotection? This review analyzes current evidence about the potential neuroprotective effects of SGLT2i in adult diabetic patients. #Neuroprotection #SGLT2i 🔬
www.mdpi.com/2227-9059/12...

Secondary analysis of the #Basel-PMI and #PMI-Vital prospective cohorts, led by Haziri et al, showing an increased risk of 90-day cardiac complications if #SGLT2i are stopped before anaesthesia as per current recommendations.

https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00353-3/fulltext